Three micro-caps debuted this past week during the IPO market’s annual February lull. Nine SPACs also priced. The pipeline remained relatively quiet, with two IPOs and one SPAC submitting initial filings. The Arena Group (AREN), a...read more
TC BioPharm Holdings, a Scottish Phase 2 biotech developing allogeneic gamma-delta T cell therapies, raised $18 million by offering 4.1 million ADSs at $4.25, as expected. The company offered 0.4 million more ADSs than anticipated. Each ADS comes with...read more
TC BioPharm Holdings, a Scottish Phase 2 biotech developing allogeneic gamma-delta T cell therapies, again lowered the proposed deal size for its upcoming IPO on Monday. The Holytown, UK-based company now plans to raise $16 million by offering 3.8 million...read more
TC BioPharm Holdings, a Scottish Phase 2 biotech developing allogeneic gamma-delta T cell therapies, lowered the proposed deal size for its upcoming IPO on Thursday. The Holytown, UK-based company now plans to raise $30 million by offering 3.8 million ADSs at...read more
US IPO Weekly Recap: 3 micro-cap IPOs come to market during the February lull
Three micro-caps debuted this past week during the IPO market’s annual February lull. Nine SPACs also priced. The pipeline remained relatively quiet, with two IPOs and one SPAC submitting initial filings. The Arena Group (AREN), a...read more
Scottish biotech TC BioPharm prices US IPO at $4.25
TC BioPharm Holdings, a Scottish Phase 2 biotech developing allogeneic gamma-delta T cell therapies, raised $18 million by offering 4.1 million ADSs at $4.25, as expected. The company offered 0.4 million more ADSs than anticipated. Each ADS comes with...read more
Scottish biotech TC BioPharm further lowers deal size by 27% ahead of $16 million US IPO
TC BioPharm Holdings, a Scottish Phase 2 biotech developing allogeneic gamma-delta T cell therapies, again lowered the proposed deal size for its upcoming IPO on Monday. The Holytown, UK-based company now plans to raise $16 million by offering 3.8 million...read more
Scottish biotech TC BioPharm lowers deal size by 40%, adds warrants ahead of $30 million US IPO
TC BioPharm Holdings, a Scottish Phase 2 biotech developing allogeneic gamma-delta T cell therapies, lowered the proposed deal size for its upcoming IPO on Thursday. The Holytown, UK-based company now plans to raise $30 million by offering 3.8 million ADSs at...read more